The Jackson Heart Study of Cardiovascular Disease Among African Americans (JHS)

July 3, 2025 updated by: National Heart, Lung, and Blood Institute (NHLBI)
This is a prospective study of the environmental and genetic factors that influence the development of cardiovascular disease (CVD) in African American adults. The cohort is a collaboration among multiple institutions (Jackson State University, Mississippi State Department of Health, Tougaloo College, and the University of Mississippi Medical Center), NIMHD, and NHLBI.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Detailed Description

The Jackson Heart Study (JHS) initiated in 1998, is a longitudinal investigation of genetic and environmental risk factors associated with the disproportionate burden of cardiovascular disease (CVD) in African American adults. In addition, the JHS conducts community education and outreach activities to promote healthy lifestyles and reduce disease risk burden, undergraduate- and graduate-level research training programs, and high school science and math enrichment programs to prepare and encourage students to pursue biomedical careers. The study recruited 5306 African American adults living in the Jackson, MS area (Hinds, Madison, and Rankin Counties). Participants were enrolled from each of 4 recruitment pools: random, 17%; volunteer, 30%; currently enrolled in the Atherosclerosis Risk in Communities (ARIC) Study, 31% (shared JHS/ARIC cohort); and secondary family members, 22%. Recruitment was limited to non-institutionalized African American adults aged 35-84 years, except in a nested family cohort where those aged 21+ years were also eligible. Among those enrolled, approximately 3,700 gave consent that allows genetic research and deposition of data into dbGaP. JHS participants have completed four clinical examinations (Exam 1, 2000-04; Exam 2, 2005-08; Exam 3, 2009-13; Exam 4, 2021-2025) that have generated extensive longitudinal data on traditional and putative CVD risk factors, socioeconomic and sociocultural factors, biochemical analytes, and measures of subclinical disease from echocardiography, cardiac magnetic resonance imaging (MRI), and computed tomography (CT) scans of the heart, aorta, and abdomen. Stored biological samples have been assayed for putative biochemical risk factors and stored for future research. DNA has been extracted and lymphocytes cryopreserved for study of candidate genes, genome-wide scanning, expression, and other -omics investigations. Participants have been contacted annually to update information, confirm vital status, document interim medical events, hospitalizations, and functional status, and obtain additional sociocultural information. Ongoing cohort surveillance includes abstraction of medical records and death certificates for relevant International Classification of Diseases (ICD) codes and adjudication of nonfatal events and deaths. The JHS serves as a resource to the scientific community for novel research, promotes cardiovascular health in the local community, and encourages students and fellows to pursue biomedical careers.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
5306

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Mississippi
      • Jackson, Mississippi, United States, 39213
        • UMMC, JSU, Tougaloo College, MSDH

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

35 years to 84 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

African-American adult residents of metropolitan Jackson, Mississippi

Description

Inclusion Criteria:

  • African American
  • Residents of Jackson, Mississippi

Exclusion Criteria:

  • Institutionalization

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Cardiovascular Disease
Time Frame: 2000-2016
Coronary Heart Disease, Stroke, Heart Failure
2000-2016

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Mortality
Time Frame: 2000-2018
All Cause
2000-2018

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
National Heart, Lung, and Blood Institute (NHLBI)

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
National Institute on Minority Health and Health Disparities (NIMHD)

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Wendy White, PhD, Tougaloo College JHS UTEC
  • Principal Investigator: Marinelle Payton, MD, PhD, Jackson State University JHS GTEC
  • Principal Investigator: April P Carson, PhD, UMMC JHS CC and FC
  • Principal Investigator: Victor Sutton, PhD, Mississippi State Department of Health JHS CEC
  • Principal Investigator: Jennifer Reneker, PhD, UMMC JHS GTEC

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 19, 2000

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 12, 2025

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 12, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 25, 2000

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 25, 2000

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 26, 2000

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 9, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 3, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 5001
  • HHSN268201800010I (Other Grant/Funding Number: NHLBI and NIMHD)
  • HHSN268201800011I (Other Grant/Funding Number: NHLBI and NIMHD)
  • HHSN268201800012I (Other Grant/Funding Number: NHLBI and NIMHD)
  • HHSN268201800013I (Other Grant/Funding Number: NHLBI and NIMHD)
  • HHSN268201800014I (Other Grant/Funding Number: NHLBI and NIMHD)
  • HHSN268201800015I (Other Grant/Funding Number: NHLBI and NIMHD)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The JHS adheres to NIH and NHLBI policies for data sharing of epidemiologic studies. Data from each cycle of an examination or follow-up component are prepared by the JHS Coordinating Center and sent to the NHLBI PO for distribution as a data set after the completion of each examination or two years after the baseline, follow-up, genetic, ancillary study, or other data set is finalized within the study for analysis for use in publication. De-identified data from Exams 1, 2 and 3 of the JHS are available and shared commonly through the JHS processes for presentation and publication and ancillary studies. Public datasets for Exam 1, Exam 2, and Exam 3 have been provided to BioLINCC and dbGaP.

IPD Sharing Time Frame

Data are currently available for exams 1, 2 and 3 and for cardiovascular events through 12/31/2016 and mortality through 12/31/2019. Data will be available indefinitely.

IPD Sharing Access Criteria

Data can accessed from JHS with approved manuscript proposals and from dbGaP and BIOLINCC.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings